What Alifax does

Alifax S.r.l. is an Italian in vitro diagnostics (IVD) manufacturer founded in 1988 and headquartered in Polverara, Italy, operating under the direction and coordination of Alifax Holding S.p.A. The company develops and produces proprietary diagnostic instruments for clinical microbiology and hematology laboratories, built on four core technology pillars: photometry capillary measurement (TEST1 2.0 and ROLLER ESR analyzers), laser light scattering (HB&L, ALFRED 60/AST, SIDECAR for bacteriology workflows), ATR-FTIR spectroscopy (I-dOne bacterial identification), and RT-PCR (Molecular Mouse with ready-to-use cartridges, including a sepsis and AMR resistance panel). Its stated product portfolio is organized into lines covering ESR, bacteriology, bacterial identification, molecular biology, AMR/MDRO screening, sepsis solutions, and sample collection and transportation, each combining an instrument with proprietary consumables or cartridges that generate recurring revenue per installed unit.

The business model is sales-led and B2B, targeting hospital and reference clinical microbiology laboratories. Alifax sells through five wholly-owned subsidiaries (Italy, Germany, Spain, Brazil, Russia) and a network of international distributors, reaching customers in more than 130 countries. Demand generation is driven by scientific marketing — peer-reviewed publications, the "Alifax INSIDE-OUT" webinar series, regional hybrid workshops, and conference participation including ESCMID — alongside virtual product demos. No public pricing, revenue figures, or funding rounds are disclosed; the company is privately held under Alifax Holding S.p.A. and certified to ISO 9001, ISO 13485, and MDSAP (covering US FDA, Health Canada, Japan PMDA, Australia TGA, and Brazil ANVISA). Recent strategic activity centers on the production launch of TEST1 2.0, the international rollout of I-dOne, and the April 2026 SMART TRAIL R&D project for bedside antibiotic synergy testing against multidrug-resistant bacteria.

Name

Alifax

Legal name

Alifax S.r.l.

Website

https://alifax.com

Company type

Private

Founded year

1988

Operating status

Operating

Headcount range

101–250 employees

Short description

Alifax S.r.l. is an Italian in vitro diagnostics manufacturer founded in 1988 that develops proprietary ESR, bacteriology, molecular, and antimicrobial susceptibility testing instruments for hospital and clinical microbiology laboratories, distributed via five subsidiaries and a global partner network across more than 130 countries.

Ownership category

akta.pro rank

Headquarters

HQ city

Polverara

HQ country

Italy

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

Alifax designs, manufactures, and distributes proprietary in vitro diagnostic instruments for clinical microbiology laboratories. Its portfolio spans ESR analyzers (TEST1 2.0, ROLLER), laser light scattering bacteriology systems (HB&L, ALFRED 60/AST, SIDECAR), an ATR-FTIR-based bacterial identification platform (I-dOne), an RT-PCR molecular diagnostics system (MOLECULAR MOUSE) with sepsis and resistance cartridges, plus integrated AMR screening, sample collection/transport solutions, and consumables.

Product overview

Alifax S.r.l. develops and manufactures innovative diagnostic instruments for laboratory diagnostics, operating in more than 130 countries. The product portfolio includes several core instrument families: the ESR Line (TEST1 2.0 and ROLLER) using photometry capillary technology for rapid erythrocyte sedimentation rate measurement; the Bacteriology Line offering automation for modern microbiology labs including HB&L laser light scattering instruments, ALFRED 60/AST for rapid antimicrobial susceptibility testing, and SIDECAR; the I-dOne next-generation bacterial identification system using infrared spectroscopy; and the MOLECULAR MOUSE RT-PCR system with ready-to-use cartridges for molecular diagnostics. The company also provides integrated solutions for sepsis management (SEPSIS Solutions), antimicrobial resistance screening (MDRO), and sample collection/transportation. All products are designed for in vitro diagnostic (IVD) purposes.

Differentiator

Problem solved

Functional benefit

Brands

• TEST1 2.0: Original ESR system with photometry capillary technology, delivering results in less than 20 seconds.
• I-dOne
• MOLECULAR MOUSE
• HB&L
• ALFRED 60/AST
• SIDECAR
• MDRO
• SEPSIS Solutions

Products and services

• TEST1 2.0 Automated erythrocyte sedimentation rate (ESR) analyzer using photometry capillary technology, providing ESR results in less than 20 seconds for clinical laboratories.
• ROLLER Manual erythrocyte sedimentation rate analyzer based on Alifax's photometry capillary technology, part of the ESR Line product family for clinical laboratories.
• I-dOne Next-generation microorganism identification system using ATR-FTIR infrared spectroscopy for rapid bacterial identification, including Legionella identification from genus to serogroup level in approximately 10 minutes.
• MOLECULAR MOUSE RT-PCR system with ready-to-use cartridges for molecular diagnostics, including a sepsis panel capable of identifying pathogens and resistance genes from positive blood cultures within approximately one hour.
• HB&L Laser light scattering instrument for rapid urine screening, dialysate culture, and detection of aerobic and anaerobic microorganisms in human biological fluids, delivering results in approximately 3 hours with >99% general agreement and negative predictive value versus classical culture methods.
• ALFRED 60/AST Rapid antimicrobial susceptibility testing system based on light scattering technology that delivers AST results from positive blood culture bottles in 5-6 hours, compared with 16-48 hours for conventional methods, with 95% categorical agreement for Gram-negative and 89% for Gram-positive isolates.
• SIDECAR Laser light scattering instrument used to automate bacteriology laboratory workflows alongside the HB&L and ALFRED 60/AST systems.
• SEPSIS Solutions Comprehensive molecular sepsis panel combining MOLECULAR MOUSE RT-PCR cartridges with rapid AST to support evidence-based antimicrobial therapy in critical patients.
• MDRO Rapid and automated phenotypic screening system for Multi Drug Resistant Organisms (MDRO/AMR) used by infection control and antimicrobial stewardship programs.
• Bacteriology Line Integrated automation solutions for the modern bacteriology laboratory, bundling culture, identification (I-dOne), and antimicrobial susceptibility testing (HB&L, ALFRED 60/AST, SIDECAR).
• Sample Collection and Transportation Pre-analytical phase optimization solutions including transport media and collection systems designed to preserve sample integrity prior to bacteriology and molecular testing.

Quantifiable outcome

• HB&L system achieves >99% general agreement and Negative Predictive Value vs classical cultural method for UTI diagnosis
• +3 more outcomes

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

One partnership is on record.

• Regione Autonoma Friuli Venezia GiuliacoreStrategic or Co-development Partner · 29 April 2026Alifax received research funding from Regione Friuli Venezia Giulia under the PR FESR FVG program for the SMART TRAIL project. This project aims to develop an innovative rapid diagnostic system for personalized and rapid antibiotic synergy evaluation against multidrug-resistant bacteria to support timely and informed therapeutic decisions in critical settings.

Scale indicators5 records

Recent moves8 records

Expansion highlights6 records

Broad incumbents

• Beckman Coulter (Danaher): Major IVD incumbent with a MicroScan AST/ID system and broader clinical chemistry/hematology menu, directly competing with Alifax's bacteriology line and ESR analyzers in hospital labs.
• bioMérieux: Global leader in clinical microbiology diagnostics with overlapping portfolios in bacterial identification (VITEK MS), antimicrobial susceptibility testing (VITEK 2), molecular sepsis panels (BIOFIRE), and blood culture (BACT/ALERT). Competes with Alifax across the full microbiology workflow in the same hospital laboratories worldwide.
• BD (Becton, Dickinson and Company): Large diversified IVD player with BD MAX molecular panels, Phoenix M50 AST, and BD EpiCenter middleware, competing with Alifax's molecular sepsis and rapid AST offerings in clinical microbiology departments.
• ELITech Group: European IVD group with microbiology, clinical chemistry and ESR offerings, competing with Alifax across multiple product lines particularly in European hospital and clinical laboratory markets.

Direct peers

• T2 Biosystems: Focused on rapid molecular diagnostics for sepsis and bloodstream infections using T2 Magnetic Resonance technology, competing with Alifax's MOLECULAR MOUSE sepsis panel in the rapid-pathogen-ID-from-blood category.
• Accelerate Diagnostics: Specialist in rapid antimicrobial susceptibility testing (Pheno system, Accelerate PhenoTest BC kit), competing head-to-head with Alifax's ALFRED 60/AST for rapid AST directly from positive blood cultures.
• ALCOR Scientific: Specialist manufacturer of automated ESR analyzers (iSED, VES-MAT 5), a direct niche competitor to Alifax's TEST1 2.0 and ROLLER in the rapid erythrocyte sedimentation rate segment.
• Bruker: Direct competitor to Alifax's I-dOne bacterial identification system through its MALDI Biotyper / IR Biotyper platforms based on mass spectrometry and FTIR spectroscopy for routine microorganism identification in clinical labs.
• Copan Diagnostics: Specialist in pre-analytical sample collection, transport media, and laboratory automation for microbiology, directly overlapping with Alifax's Sample Collection & Transportation line and bacteriology workflow automation.

Emerging players

• Q-linea: Swedish developer of the ASTar rapid AST system for bloodstream infections, a direct emerging competitor to ALFRED 60/AST targeting the same clinical microbiology use case.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UCPmf8mf9p7H9ucQ9YjdsggQ
• Xx.com/Alifax_SpA
• LinkedInlinkedin.com/company/alifax-spa

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Alifax